Clinical trials: Gemcitabine
Pancreatic Neoplasms, Cancer of the Pancreas
Gemcitabine and CT-011 for Resected Pancreatic Cancer
Background: In 2009, 49,096 patients were diagnosed with pancreatic cancer. Pancreatic cancer carries a poor prognosis with an overall 5-year relative survival rate of 5.6%.
- Conditions
- Pancreatic Neoplasms, Cancer of the Pancreas, Neoplasms Pancreatic, Pancreatic Cancer
- Trial name
- NCT01313416
- Testing
- CT-011, Gemcitabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Augusta University
Head and Neck Cancer
S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00100789
- Testing
- gemcitabine, paclitaxel
- Where
- 123 sites in United States
- Volunteers
- 67 people
- Sponsor
- SWOG Cancer Research Network
Pancreatic Neoplasms, Cancer of Pancreas
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
This clinical trial adds high-dose ascorbate (vitamin C) to the standard of care regimen for metastatic pancreatic adenocarcinoma (a type of pancreatic cancer).
- Conditions
- Pancreatic Neoplasms, Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic
- Trial name
- NCT02905578
- Testing
- Gemcitabine, nab-paclitaxel, Pharmacological ascorbate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Iowa
Lung Neoplasms
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
The purpose of this study is to help answer: Whether pemetrexed, gemcitabine and/or carboplatin can shrink tumor(s) or make tumor(s) disappear in patients with relapsed lung cancer (lung cancer that has come back after surgical…
- Trial name
- NCT00356525
- Testing
- pemetrexed, gemcitabine, carboplatin
- Where
- 17 sites in United States, Brazil and 1 more
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Urothelial Carcinoma, Bladder Cancer
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
The purpose of this trial is to determine the benefit of the combination of nab-paclitaxel plus gemcitabine given for 6 cycles, followed by maintenance nab-paclitaxel alone, in patients with cisplatin-ineligible or…
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Transitional Cell Carcinoma
- Trial name
- NCT02887248
- Testing
- nab-paclitaxel, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- SCRI Development Innovations, LLC
Pancreatic Neoplasm
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
This study aims to seek evidence that activation of certain cells of the immune system will be safe and well tolerated in combination with cytotoxic chemotherapy.
- Trial name
- NCT00711191
- Testing
- monoclonal antibody, chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
This Phase 3 trial is a randomized, double-blind, placebo-controlled trial of gemcitabine in combination with TH-302 compared to gemcitabine in combination with placebo in subjects with locally advanced unresectable or metastatic…
- Trial name
- MAESTRO (NCT01746979)
- Testing
- TH-302, Gemcitabine
- Where
- 2 sites in United States, Germany
- Volunteers
- 693 people
- Sponsor
- ImmunoGenesis
Pancreatic Adenocarcinoma
Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
The research trial is testing the experimental treatment MSC1936369B in combination with Gemcitabine, in subjects with metastatic pancreatic adenocarcinoma.
- Trial name
- NCT01016483
- Testing
- Pimasertib, Gemcitabine
- Where
- 2 sites in United States, Germany
- Volunteers
- 141 people
- Sponsor
- EMD Serono
Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
This phase Ib/II trial studies the best dose of carboplatin when given together with berzosertib, gemcitabine and pembrolizumab and to see how well it works in treating patients with stage IV squamous cell non-small cell lung…
- Trial name
- NCT04216316
- Testing
- Berzosertib, Biospecimen Collection, Carboplatin
- Where
- 34 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin's Disease
Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease
The goal of this clinical research study is to learn if fludarabine, melphalan and gemcitabine followed by transplantation of stem cells (blood-forming cells) as well as immune cells (lymphocytes), collected from a matched…
- Trial name
- NCT00385788
- Testing
- Gemcitabine, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
The investigator is developing an immune therapy against pancreatic cancer. Immune cells, known as "T cells with tumor killing capacity", are involved in this immune therapy.
- Trial name
- NCT03848182
- Testing
- Gemcitabine, TT vaccine booster
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Non-small Cell Lung Cancer Metastatic
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
Response rates. Changes in tumor blood flow.
- Trial name
- NA_00067809 (NCT01752023)
- Testing
- Cisplatin + Gemcitabine with SUBATM-itraconazole, Cisplatin + Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
This observational study will evaluate the impact of rash on survival of patients with metastatic pancreatic cancer treated with erlotinib plus gemcitabine. Further, clinical effectiveness, efficacy and safety will be assessed.
- Trial name
- NCT01782690
- Testing
- erlotinib, gemcitabine
- Where
- Germany
- Volunteers
- 338 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-cell Lymphoma
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma…
- Trial name
- NCT05498220
- Testing
- Polatuzumab vedotin (PV), Rituximab, Hyaluronidase
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Pancreatic Cancer
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
The purpose of this study is to determine whether patients with locally advanced pancreatic cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared to patients who receive standard of care…
- Trial name
- LAPC (NCT01395017)
- Testing
- dasatinib
- Where
- 74 sites in United States, Australia and 13 more
- Volunteers
- 202 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Solid Tumor, Pancreatic Cancer
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
This is a Japanese Phase 1, open-label, and dose-escalating trial of TH-302 as monotherapy in subjects with solid tumors and in combination with gemcitabine in subjects with pancreatic cancer.
- Trial name
- NCT01833546
- Testing
- Evofosfamide, Gemcitabine
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Biliary Tract Cancer
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer.
- Trial name
- NCT04163900
- Testing
- NUC-1031, Gemcitabine, Cisplatin
- Where
- 125 sites in United States, Australia and 13 more
- Volunteers
- 773 people
- Sponsor
- NuCana plc
Inoperable Locally Advanced or Metastatic Biliary Tract Cancer
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
The objective of this study is to investigate the safety and tolerability of oral dose of selumetinib in combination with chemotherapies (cisplatin and gemcitabine) in Japanese patients with advanced biliary tract cancer (BTC).
- Trial name
- NCT01949870
- Testing
- Cisplatin, Gemcitabine, Selumetinib
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
This study will compare the efficacy and safety of escalating versus standard doses to rash of Tarceva, in combination with gemcitabine, in patients with metastatic pancreatic cancer.
- Trial name
- NCT00652366
- Testing
- Erlotinib, escalating dose, Erlotinib, standard dose, Gemcitabine
- Where
- 89 sites in Argentina, Australia and 21 more
- Volunteers
- 467 people
- Sponsor
- Hoffmann-La Roche
Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase I trial studies the side effects and best dose of gemcitabine hydrochloride and berzosertib when given together with carboplatin in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has…
- Conditions
- Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor
- Trial name
- NCT02627443
- Testing
- Berzosertib, Carboplatin, Gemcitabine Hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)